[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Day One Biopharmaceuticals Inc (DAWN)

Day One Biopharmaceuticals Inc (DAWN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,224,781
  • Shares Outstanding, K 103,334
  • Annual Sales, $ 158,180 K
  • Annual Income, $ -107,320 K
  • EBIT $ -128 M
  • EBITDA $ -124 M
  • 60-Month Beta -1.74
  • Price/Sales 14.04
  • Price/Cash Flow N/A
  • Price/Book 5.01
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.03
  • Most Recent Earnings $-0.20 on 02/24/26
  • Next Earnings Date 05/05/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 7
  • High Estimate $-0.09
  • Low Estimate $-1.04
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) +11.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.34 +0.89%
on 03/24/26
21.53 unch
on 04/22/26
+0.09 (+0.42%)
since 03/20/26
3-Month
9.97 +115.95%
on 03/03/26
21.53 unch
on 04/22/26
+9.19 (+74.47%)
since 01/22/26
52-Week
5.64 +282.08%
on 08/06/25
21.53 unch
on 04/22/26
+14.20 (+193.72%)
since 04/22/25

Most Recent Stories

More News
Servier completes the acquisition of Day One Biopharmaceuticals

SURESNES, France , April 23, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer...

DAWN : 21.53 (+0.19%)
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RLYB : 8.80 (+0.23%)
WSR : 18.92 (unch)
TERN : 52.94 (-0.02%)
DAWN : 21.53 (+0.19%)
Are SEM, DAWN, VRE Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

VRE : 18.96 (+0.21%)
SEM : 16.45 (unch)
DAWN : 21.53 (+0.19%)
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals...

DAWN : 21.53 (+0.19%)
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

DAWN : 21.53 (+0.19%)
TALK : 5.19 (+0.19%)
UNF : 257.69 (-0.20%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--DAWN, SEM, FONAR, and JHG

NEW YORK , March 11, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

JHG : 51.57 (-0.02%)
SEM : 16.45 (unch)
DAWN : 21.53 (+0.19%)
FONR : 18.89 (+0.16%)
Are DAWN and TALK Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

DAWN : 21.53 (+0.19%)
TALK : 5.19 (+0.19%)
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals...

DAWN : 21.53 (+0.19%)
Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , March 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Day One (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

DAWN : 21.53 (+0.19%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)

NEW YORK , March 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions...

DAWN : 21.53 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One Biopharmaceuticals Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 21.58
2nd Resistance Point 21.56
1st Resistance Point 21.54
Last Price 21.53
1st Support Level 21.50
2nd Support Level 21.48
3rd Support Level 21.46

See More

52-Week High 21.53
Last Price 21.53
Fibonacci 61.8% 15.46
Fibonacci 50% 13.58
Fibonacci 38.2% 11.71
52-Week Low 5.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.